免疫毒素BDI-1-PEA膀胱灌注预防膀胱癌术后复发的临床研究  

Intravesical use of immunotoxin BDI-1-PEA for preventing the postoperative recurrence of bladder cancer

作　　者：薛松[1] 温儒民[1] 孙晓青[1] 陈家存[1] 顾骧[1] 陈仁富[1] 郑骏年[1] 

机构地区：[1]徐州医学院附属医院泌尿外科,江苏徐州221002

出　　处：《徐州医学院学报》2002年第5期398-400,共3页Acta Academiae Medicinae Xuzhou

基　　金：江苏省教委自然科学基金资助课题 (98KJB32 0 0 0 7)

摘　　要：目的　应用新型免疫毒素BDI- 1-PEA膀胱灌注 ,探讨其对预防人膀胱癌术后复发的作用。方法　 12例膀胱移行细胞癌术后患者应用 10 0倍半细胞致死剂量浓度 (1× 10 - 7mol L)抗人膀胱癌免疫毒素BDI- 1-PEA5 0ml行膀胱内灌注 ,药物在膀胱内保留 1h后排出 ,每周灌注 2次 ,10次为一疗程。同期随机 8例膀胱移行细胞癌术后患者应用丝裂霉素 2 0mg膀胱灌注作为对照 ,每周灌注 1次 ,8次后改为每月 1次 ,10次为 1疗程。每 3个月复查膀胱镜或B超检查。结果　免疫毒素组用药后随访 7～ 16个月 ,平均 12个月 ;12例病人均无复发 ,多次膀胱镜检查未见异常。丝裂霉素组随访 9～ 15个月 ,平均 11个月 ;2例复发。结论　免疫毒素BDI- 1-PEA对预防膀胱癌术后复发有较好疗效。Objective To study the effect of conjugate immunotoxin BDI-1-PEA given intravesically on preventing bladder cancer from recurring in postoperative patients. Methods The conjugate BDI-1-PEA was given intravesically to 12 bladder cancer patients after the surgery. The conjugate was diluted to the concentration of 1×10 -7 mol/L, 50 ml of it was used for vesical retention irrigation twice a week for 10 times. 8 control patients were treated with intravesical mitomycin 20 mg diluted to 30 ml, given once a week for 8 times and then once a month for 2 times. All patients were followed up for 7～15 months, with an average of 12 months. Results The 12 patients treated with intravesical BDI-1-PEA were all free from recurrence, while among the 8 controls, two suffered from recurrent cancer in 10 and 12 months. Conclusion BDI-1-PEA conjugate mnay be an effective immunotoxin against human bladder cancer, and is a promising candidate for further study on its long-term efficacy.

关 键 词：免疫毒素 BDI-1-PEA 膀胱灌注 预防 膀胱癌 术后复发 临床研究 

分 类 号：R737.14[医药卫生—肿瘤]